文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

单倍体联合脐血移植治疗难治性重型再障及低增生性MDS

Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome.
PubMed 文献 · Br J Haematol · 2021-05-15

一项前瞻性2期试验评估单倍体供者CD34+精选细胞与单一脐血单位共输注的移植方案,治疗29例难治性重型再生障碍性贫血患者(含10例演变为MDS),中位年龄20岁。

要点

  • 单倍体联合脐血移植中性粒细胞植入率97%、血小板植入率93%,植入迅速。
  • 为缺乏HLA相合供者的难治性SAA及低增生性MDS提供替代选择。

核心结论

  • 单倍体联合脐血移植植入良好、长期结局优异,可作为缺乏HLA相合供者难治性SAA及低增生性MDS的替代选择。

研究设计与样本

  • 前瞻性2期试验,纳入29例难治性重型再生障碍性贫血患者(其中10例演变为MDS),中位年龄20岁。
  • 移植方案为单一脐血单位与单倍体亲属CD34+精选细胞共输注。

主要发现

  • 97%患者中性粒细胞恢复(中位10天),93%患者血小板恢复(中位32天)。
  • 早期髓系植入来自单倍体供者,多数患者逐渐被脐血的持久植入替代。
  • II-IV级急性GVHD累积发生率21%,慢性GVHD累积发生率41%。
  • 单倍体对脐血KIR配体不合的移植脐血植入延迟。

临床怎么用

  • 对缺乏HLA相合供者的难治性SAA及低增生性MDS患者,可考虑单倍体联合脐血移植。

局限性

  • 为单臂2期试验,样本量29例,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Umbilical cord blood (UCB) transplantation is a potentially curative treatment for patients with refractory severe aplastic anaemia (SAA), but has historically been associated with delayed engraftment and high graft failure and mortality rates. We conducted a prospective phase 2 trial to assess outcome of an allogeneic transplant regimen that co-infused a single UCB unit with CD34+ -selected cells from a haploidentical relative. Among 29 SAA patients [including 10 evolved to myelodysplastic syndrome (MDS)] who underwent the haplo cord transplantation (median age 20 years), 97% had neutrophil recovery (median 10 days), and 93% had platelet recovery (median 32 days). Early myeloid engraftment was from the haplo donor and was gradually replaced by durable engraftment from UCB in most patients. The cumulative incidences of grade II-IV acute and chronic graft-versus-host disease (GVHD) were 21% and 41%, respectively. With a median follow-up of 7·5 years, overall survival was 83% and GVHD/relapse-free survival was 69%. Patient- and transplant-related factors had no impact on engraftment and survival although transplants with haplo-versus-cord killer-cell immunoglobulin-like receptor (KIR) ligand incompatibility had delayed cord engraftment. Our study shows haplo cord transplantation is associated with excellent engraftment and long-term outcome, providing an alternative option for patients with refractory SAA and hypoplastic MDS who lack human leucocyte antigen (HLA)-matched donors.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Childs RW, Tian X, Vo P, et al. Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. Br J Haematol. 2021. PMID: 33993466. doi:10.1111/bjh.17406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。